159 related articles for article (PubMed ID: 34327500)
1. Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States.
Baum SJ; Rane PB; Nunna S; Habib M; Philip K; Sun K; Wang X; Wade RL
Am J Prev Cardiol; 2021 Jun; 6():100177. PubMed ID: 34327500
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
[TBL] [Abstract][Full Text] [Related]
3. Moderate-Intensity Statin With Ezetimibe Combination Therapy vs High-Intensity Statin Monotherapy in Patients at Very High Risk of Atherosclerotic Cardiovascular Disease: A Post Hoc Analysis From the RACING Randomized Clinical Trial.
Lee SJ; Cha JJ; Choi WG; Lee WS; Jeong JO; Choi S; Cho YH; Park W; Yoon CH; Lee YJ; Hong SJ; Ahn CM; Kim BK; Ko YG; Choi D; Hong MK; Jang Y; Hong SJ; Kim JS;
JAMA Cardiol; 2023 Sep; 8(9):853-858. PubMed ID: 37531130
[TBL] [Abstract][Full Text] [Related]
4. LOGAN-CV: A Prospective Study of a Multifaceted Intervention Targeting United States Clinicians to Improve Guideline-Based Management of Lipid-Lowering Therapy.
McKoy JN; Kalich BA; Greene L; Mackey RH; Rosenthal NA; Khan Y; Wójcik C; Jones J; Carabuena LA
Adv Ther; 2024 Jan; 41(1):451-463. PubMed ID: 37989909
[TBL] [Abstract][Full Text] [Related]
5. Antihyperlipidemic Medication Treatment Patterns and Statin Adherence Among Patients with ASCVD in a Managed Care Plan After Release of the 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol.
Bellows BK; Olsen CJ; Voelker J; Wander C
J Manag Care Spec Pharm; 2016 Aug; 22(8):892-900. PubMed ID: 27459651
[TBL] [Abstract][Full Text] [Related]
6. Patient characteristics and acute cardiovascular event rates among patients with very high-risk and non-very high-risk atherosclerotic cardiovascular disease.
Fonarow GC; Kosiborod MN; Rane PB; Nunna S; Villa G; Habib M; Arellano J; Mues KE; Sun K; Wade RL
Clin Cardiol; 2021 Oct; 44(10):1457-1466. PubMed ID: 34351003
[TBL] [Abstract][Full Text] [Related]
7. Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline.
Alanaeme CJ; Bittner V; Brown TM; Colantonio LD; Dhalwani N; Jones J; Kalich B; Exter J; Jackson EA; Levitan EB; Poudel B; Wang Z; Woodward M; Muntner P; Rosenson RS
Am Heart J Plus; 2022 Sep; 21():. PubMed ID: 37168932
[TBL] [Abstract][Full Text] [Related]
8. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.
Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG
Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572
[TBL] [Abstract][Full Text] [Related]
9. Effect of 2013 ACC/AHA Blood Cholesterol Guidelines on Statin Treatment Patterns and Low-Density Lipoprotein Cholesterol in Atherosclerotic Cardiovascular Disease Patients.
Okerson T; Patel J; DiMario S; Burton T; Seare J; Harrison DJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28314797
[TBL] [Abstract][Full Text] [Related]
10. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
[TBL] [Abstract][Full Text] [Related]
11. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
Rosenblit PD
Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
[TBL] [Abstract][Full Text] [Related]
12. Adoption of the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline in Cardiology Practices Nationwide.
Pokharel Y; Tang F; Jones PG; Nambi V; Bittner VA; Hira RS; Nasir K; Chan PS; Maddox TM; Oetgen WJ; Heidenreich PA; Borden WB; Spertus JA; Petersen LA; Ballantyne CM; Virani SS
JAMA Cardiol; 2017 Apr; 2(4):361-369. PubMed ID: 28249067
[TBL] [Abstract][Full Text] [Related]
13. Ezetimibe Use and LDL-C Goal Achievement: A Retrospective Database Analysis of Patients with Clinical Atherosclerotic Cardiovascular Disease or Probable Heterozygous Familial Hypercholesterolemia.
Menzin J; Aggarwal J; Boatman B; Yu J; Stern K; Harrison DJ; Patel JG
J Manag Care Spec Pharm; 2017 Dec; 23(12):1270-1276. PubMed ID: 29172973
[TBL] [Abstract][Full Text] [Related]
14. Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified.
Baum SJ; Wade RL; Xiang P; Arellano J; Cerezo Olmos C; Nunna S; Chen CC; Carter CM; Desai NR
Ther Clin Risk Manag; 2019; 15():1325-1332. PubMed ID: 32009789
[TBL] [Abstract][Full Text] [Related]
15. Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients.
Chen CC; Rane PB; Hines DM; Patel J; Harrison DJ; Wade RL
Ther Clin Risk Manag; 2018; 14():2425-2435. PubMed ID: 30587999
[TBL] [Abstract][Full Text] [Related]
16. Utilization Patterns of Lipid-lowering Therapies in Patients With Atherosclerotic Cardiovascular Disease or Diabetes: A Population-based Study in South Korea.
Kim S; Kim H; Kim E; Han S; Rane PP; Fox KM; Zhao Z; Qian Y; Suh HS
Clin Ther; 2018 Jun; 40(6):940-951.e7. PubMed ID: 29735297
[TBL] [Abstract][Full Text] [Related]
17. Atherosclerotic Cardiovascular Disease Events in Adults With CKD Taking a Moderate- or High-Intensity Statin: The Chronic Renal Insufficiency Cohort (CRIC) Study.
Poudel B; Rosenson RS; Bittner V; Gutiérrez OM; Anderson AH; Woodward M; Deo R; Carson AP; Mues KE; Dluzniewski PJ; Jaar BG; Lora CM; Taliercio J; Muntner P; Colantonio LD;
Kidney Med; 2021; 3(5):722-731.e1. PubMed ID: 34693254
[TBL] [Abstract][Full Text] [Related]
18. Gaps in Guideline-Based Lipid-Lowering Therapy for Secondary Prevention in the United States: A Retrospective Cohort Study of 322 153 Patients.
Navar AM; Kolkailah AA; Gupta A; Gillard KK; Israel MK; Wang Y; Peterson ED
Circ Cardiovasc Qual Outcomes; 2023 Aug; 16(8):533-543. PubMed ID: 37529931
[TBL] [Abstract][Full Text] [Related]
19. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics, patterns of lipid-lowering medication use, and health care resource utilization and costs among patients with atherosclerotic cardiovascular disease.
Power TP; Ke X; Zhao Z; Bonine NG; Cziraky MJ; Grabner M; Barron JJ; Quimbo R; Vangerow B; Toth PP
Vasc Health Risk Manag; 2018; 14():23-36. PubMed ID: 29440909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
